Currently, there are relatively few studies on PD-L1 inhibitor monotherapy for the treatment of advanced HCC, which is still mainly based on combination therapy, and it is expected that more PD-L1 inhibitor monotherapies can be put into clinical studies in the future in order to find a suitable answer. Here, CD274 is linked to hepatocellular carcinoma.